Hypera (HYPE3) Q2 2025 earnings summary

Executive summary

• Sell-out in the pharmaceutical retail channel grew 5.5% year-over-year in 2Q25, accelerating to 8.4% in May–July, outpacing market growth.

• Net revenue reached R$2,153.9 million in 2Q25, down 1.6% year-over-year, impacted by working capital optimization and lower institutional/non-retail sales.

• EBITDA margin from continuing operations was 33.7%, stable versus 2Q24, reflecting operational efficiency and cost discipline.

• Working capital optimization concluded ahead of schedule, reducing receivables days to 60 (from 116) and working capital investments to 32% of net revenue (from 49%), the lowest in company history.

• New Board of Directors and shareholders' agreement established, consolidating a 53% controlling block to enhance governance.

Financial highlights

• Gross profit was R$1,295.1 million in 2Q25, with a gross margin of 60.1%, down 0.8 p.p. year-over-year due to product mix changes.

• EBITDA from continuing operations was R$725.4 million, down 3.9% year-over-year; margin at 33.7%.

• Net income from continuing operations was R$426.1 million in 2Q25, down 13.4% year-over-year.

• Free cash flow was R$204.6 million in 2Q25, down 55.4% year-over-year; net debt after hedge at R$7,614.6 million, 2.6x annualized EBITDA.

• EPS for the quarter was R$0.68, down 13.3% from 2Q24.

Outlook and guidance

• Working capital optimization expected to generate up to R$2.5 billion in operational cash flow by 2028 and R$7.5 billion over 10 years.

• Sell-out growth of around 8% anticipated to be maintained for the remainder of 2025; 2026 expected to be similar, pending budget process.

• Focus remains on deleveraging in the short term, with M&A considered for the mid- to long-term.

• Continued investment in innovation, marketing, and production capacity to support medium- and long-term growth.